www.interpharma.co.th IP_OCS/011/2020 8th June 2020 Subject: Notify the Resolutions of the Board of Directors Meeting, Change of Objectives of Funds Usage, Acquisition of Assets, The Issuance of Debentures and Fix the
) % Increase/ (Decrease) Total assets 183.22 649.62 466.40 254.56% Total liabilities 92.66 99.83 7.17 7.74% Total equity 90.56 549.79 459.23 507.10% Total assets Total assets were mainly consisted of cash and
or Other Assets for Management Company dated 9 September 1999; (3) Notification of the Office of the Securities and Exchange Commission No. SorNor. 33/2543 Re: Acts that may Create Conflict of Interest
-642.50% YoY mainly due to the amortization of intan- gible assets arising from investments in associate. Finance costs In 1Q2023, finance costs were THB 0.06 million, a mere increase of +1.40% YoY. Income
specific investors (Private Placement), the Company will choose specifically the investors from the capability to enhance company’s financial strength and the synergy creation from being an business partner
the capability to enhance company’s financial strength and the synergy creation from being an business partner. Two investors are strategic investor and also have extensive investment experience in
the Notification of the Capital Market Subsidiary Board No.Torchor20/2551 Re: Rules on entering into Material Transactions Deemed as Acquisition or Disposal of Assets and Notification of the Board of
. Financial Analysis of the company As of March 31, 2018, the Company has financial position that changed from its financial status as of December 31, 2017. The changes are described as follows: Assets Items
– Costs of Sales) to Sales Net profit margin = Net Profit to Total Revenues Debt to Equity = Total Liabilities to Total Equity Return on Assets (ROA) = Profit before financial costs and income tax to